Peptides are behind the world’s fastest-growing class of weight-loss drugs.

Beyond weight loss, they are being developed for cancer, hormonal disorders, and rare diseases. The global peptide therapeutics market is racing toward $50 billion, and India is positioning itself as a key manufacturing hub.

But building a peptide drug requires a precise, step-by-step chemical assembly process that depends entirely on specialty chemicals most investors have never heard about.

Alkyl Amines Chemicals Limited (AACL) is India’s largest specialty amine manufacturer, the sole global producer of several amine molecules, supplying pharmaceutical companies across India, Europe, and the United States. As the world scales up peptide drug manufacturing, the chemical inputs required trace back directly to Alkyl Amines.

Perhaps anticipating this amine tailwind, the market is beginning to price it in on the stock level.

1-Year Stock Price Movement

👁 Alkyl Amines GLP-1 opportunity

Source: http://www.tradingView.com

Understanding the business

Alkyl Amines Chemicals Limited, incorporated in 1979 and headquartered in Pune, is India’s largest and most diversified manufacturer of aliphatic amines, amine derivatives, and specialty chemicals.

The company operates three manufacturing sites and twelve production plants, serving customers across pharmaceuticals, agrochemicals, rubber processing, water treatment, and industrial solvents, both in India and globally.

Here is a simple way to understand what AACL actually does:

Take an ammonia molecule and replace its hydrogen atoms with carbon-based chains. You get an entirely new class of chemicals called amines.

Indicative structure of Amines

👁 Alkyl Amines GLP-1 opportunity

These amines then become the building blocks for drugs, pesticides, solvents, surfactants, and dozens of other industrial products.

The chemistry is hazardous. The know-how takes decades to build. Regulatory and safety barriers are genuinely high. That combination is why AACL has built durable positions in markets where very few competitors dare to enter.

The proof is in a single line from the company’s own product disclosures: AACL is the global leader in Synthetic Acetonitrile, DMAHCL, Triethylamine, and Diethylhydroxylamine, and is the sole global producer of several specialty amines.

Sole global producer.

In certain molecules, if AACL stops making them, the world’s supply simply stops. There is no Plan B.

Segments and revenue contribution

The company formally reports under a single operating segment, Specialty Chemicals. But internally, its product portfolio spans three distinct layers, each with different margin profiles.

Segmental revenue breakup (FY25)

👁 Alkyl Amines GLP-1 opportunity

Source: FY25 Annual Report

1) Aliphatic Amines (Methylamines, Ethylamines, and other base amines) form the foundational layer of the business. These are produced directly from ammonia and act as the core raw materials for most downstream products, with the methylamines segment alone catering to over 100 KTPA of Indian domestic demand.

The methylamines chain, monomethylamine, dimethylamine, and trimethylamine, are increasingly becoming more commoditised.

Indian domestic methylamine demand is approximately 100 KTPA. With new capacity from multiple players now commissioned or under construction, utilisation across the industry has fallen, and pricing pressure is real.

AACL is running methylamine capacity at between 60% and 85% utilisation, per management commentary on the Q4 FY26 earnings call. The competitive moat in this sub-segment has materially narrowed.

2) Amine Derivatives represent the value-added layer, where products like DMAHCL (Dimethylamine Hydrochloride), Triethylamine, Diethylhydroxylamine, and DIPEA (Diisopropylethylamine) are manufactured through further chemical transformation of base amines.

This segment carries materially higher margins and stronger entry barriers due to process complexity and purity requirements.

Molecular structures of key amines derivatives

This is also where AACL’s competitive position is most durable.

DMAHCL is the key raw material for metformin, the world’s most widely prescribed anti-diabetic drug. Aarti Drugs, the leading global metformin producer, is also the largest single domestic consumer of DMAHCL, and AACL has historically been a primary supplier.

Triethylamine, Diisopropyl Ethylamine, and Diethylhydroxylamine go into antibiotic synthesis, peptide chemistry, and high-purity process chemistry applications where specification requirements effectively screen out low-cost alternatives.

3) Specialty Chemicals, led by Acetonitrile, sit at the top of the margin pyramid. Acetonitrile is a high-purity solvent widely used in pharmaceutical analysis, HPLC (High-Performance Liquid Chromatography), and chemical synthesis, with AACL operating 30,000 TPA (Tonnes Per Annum) capacity and deriving nearly 15% of revenue from the product.

AACL holds 30,000 TPA of synthetic acetonitrile capacity, a scale that very few global players can match.

For most of FY25 and FY26, acetonitrile prices were near a six-year low, and this was the single biggest weight on AACL’s margins. That is now changing. As of Q4 FY26, acetonitrile selling prices in India crossed Rs 200 per kg. Globally, prices have been firming: Europe rose 3.85% quarter on quarter in Q1 2026, and supply disruptions from Strait of Hormuz shipping constraints tightened acrylonitrile runs globally, directly reducing crude acetonitrile volumes available for purification.

In India specifically, the pharmaceutical sector, which accounts for 55% of domestic acetonitrile consumption, continues to grow steadily as Active Pharmaceutical Ingredient (API) exports expand. The sector is beginning to breathe again.

The Peptide Synthesis opportunity

This may be one of the most overlooked parts of the Alkyl Amines story.

When Glucagon-Like Peptide-1 (GLP-1) drugs such as semaglutide, the active ingredient behind Ozempic and Wegovy, lost patent protection in India in March 2026, Indian pharma companies moved fast. Sun Pharma, Dr. Reddy’s, Zydus, Glenmark, Torrent, Natco, and Alkem either launched or announced generic GLP-1 therapies. But while the market focused on the drug makers, very few looked upstream at the chemistry enabling peptide production.

That is where Alkyl Amines quietly fits in.

GLP-1 therapies are peptide-based drugs, and peptide synthesis depends on specialised amine chemistry. Alkyl Amines manufactures DIPEA (Diisopropylethylamine), also known as Hunig’s Base, a key reagent used in peptide synthesis. The company also produces DBU (1,8-Diazabicyclo[5.4.0]undec-7-ene), DMPU (Dimethylpropyleneurea), TMEDA (Tetramethylethylenediamine), and high-purity Acetonitrile, used across advanced pharmaceutical synthesis and complex reaction systems.

These are not low-end commodity chemicals where suppliers can be swapped easily. In peptide manufacturing, purity, consistency, and reliability are critical.

That is what makes the opportunity structurally interesting. As India’s pharmaceutical and CDMO (Contract Development and Manufacturing Organization) ecosystem scales peptide manufacturing, demand for these upstream specialty amines could quietly compound alongside it. The market still largely views Alkyl Amines through cyclical amine spreads and short-term margin pressure, while an entirely different long-duration pharmaceutical manufacturing trend may already be building underneath.

What the numbers say

FY26 was operationally subdued, with revenue declining marginally despite one of the sharpest raw material cost shocks in recent years. Ammonia prices nearly doubled during FY25-FY26 due to geopolitical tensions in the Middle East and supply chain tightness.

👁 Alkyl Amines GLP-1 opportunity

Source: Q4 FY26 Concall

The important takeaway is not the flat revenue growth. It is the resilience underneath.

Despite ammonia costs nearly doubling, AACL managed to maintain volumes, protect margins, and keep net profit largely unchanged, a strong indicator of pricing power and customer stickiness in specialty amine chemistry.

Growth opportunities

Three factors could meaningfully shape the Alkyl Amines story over the next 12–24 months.

First, the Acetonitrile cycle appears to be turning. Global prices have started recovering, and AACL’s Q4 FY26 realisations already reflect improving market conditions. While Acetonitrile contributes only ~15% of revenue, it sits at the top of the margin pyramid, meaning even moderate price improvements can disproportionately expand EBITDA margins.

Second, India’s GLP-1 and peptide manufacturing ecosystem is beginning to scale rapidly following the expiry of semaglutide patents in India. This creates structural demand for specialty reagents like DIPEA (Diisopropylethylamine), DBU (1,8-Diazabicyclo[5.4.0]undec-7-ene), and high-purity Acetonitrile, where AACL already has manufacturing capabilities.

Unlike commodity chemicals, these applications require high purity, process consistency, and reliable supply relationships.

Third, the broader pharmaceutical opportunity remains strong. Pharma already contributes 50-60% of AACL’s revenue base, and India’s API and CDMO ecosystem continues to expand as global companies diversify sourcing away from China. As pharmaceutical manufacturing scales, demand for upstream amine intermediates is likely to grow alongside it.

Capex plans

Management remains conservative on capital allocation, guiding Rs 80-90 crore of capex across FY27-FY28, largely focused on ongoing projects and maintenance spending.

👁 Alkyl Amines GLP-1 opportunity

Source: http://www.screener.in and Q4 FY26 concall

Management has also indicated that major R&D-led expansion decisions will be deferred until market conditions stabilise, reflecting a cautious approach toward balance sheet deployment.

While management has not disclosed targeted asset turns for the Kurkumbh expansion, the specialty-focused nature of the capex and Alkyl Amines’ historical capital efficiency suggests the project is likely aimed more at improving product mix and incremental profitability than pure volume-led growth.

Valuations

At a trailing EV/EBITDA of ~28x, AACL does not appear cheap at first glance. However, current profitability remains well below the levels the business has historically delivered during stronger specialty chemical cycles, particularly when Acetonitrile spreads were healthier and specialty products contributed more meaningfully to margins.

If operating conditions normalise over FY27-FY28 through improving Acetonitrile realisations, better specialty mix, and recovery in industry spreads, the valuation could moderate materially on forward earnings.

EV/EBITDA movement over 1 year

👁 Alkyl Amines GLP-1 opportunity

Source: http://www.screener.in

That is still not cheap. But consider what the multiple is buying.

A business with global market leadership in multiple molecules, sole global producer status in certain specialty amines, a debt-free balance sheet, Rs 238 crore in annual operating cash flows, and an upstream position in India’s entire peptide synthesis build-out. Very few Indian chemical companies sit at the intersection of an amine cycle recovery, a GLP-1 manufacturing scale-up, and a China Plus One sourcing shift simultaneously. AACL does.

The bigger question is not whether the opportunities are real. They clearly are. The question is whether execution keeps pace with the thesis. Whether the Kurkumbh facility ramps on schedule, whether DIPEA volumes scale as Indian CDMOs build out peptide capacity, and whether acetonitrile pricing holds above Rs 200 per kg.

That is ultimately what this investment thesis comes down to.

Note: We have relied on data from http://www.Screener.in and http://www.tijorifinance.com throughout this article. Only in cases where the data was not available, have we used an alternate, but widely used and accepted source of information.

Rahul Rao has helped conduct financial literacy programmes for over 1,50,000 investors. He has also worked at an AIF, focusing on small and mid-cap opportunities.

Disclosure: The writer or his dependents do not hold shares in the securities/stocks/bonds discussed in the article.

The website managers, its employee(s), and contributors/writers/authors of articles have or may have an outstanding buy or sell position or holding in the securities, options on securities or other related investments of issuers and/or companies discussed therein. The content of the articles and the interpretation of data are solely the personal views of the contributors/writers/authors. Investors must make their own investment decisions based on their specific objectives, resources and only after consulting such independent advisors as may be necessary.